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Medullary thyroid carcinoma occurs in both sporadic (75%) and hereditary (25%) forms. The missense mutations of RET
proto-oncogene in MTC development have been well demonstrated. To investigate the spectrum of predominant RET germline
mutationsin exons 10, 11, and 16 in hereditary MTC in Iranian population, 217 participants were included. Genomic DNAs were
extracted from the leukocytes using the standard Salting Out/Proteinase K method. Mutation detection was performed through
PCR-RFLP and DNA sequencing. In 217 participants, 43 missense mutations were identiﬁed in exons 10 (6%), 11 (13%), and 16
(0.9%). Moreover, a novel germline mutation was detected in exon 11 (S686N). Also four diﬀerent polymorphisms were found in
intron 16 in eight patients. The obtained data showed the frequency proﬁle of RET mutations in Iranian individuals with MTC
(19.8%). The most frequent mutation in our population was C634G whereas in most population it was C634R. Altogether, these
results underline the importance of the genetic background of family members of any patient with MTC.
1.Introduction
Thyroid carcinoma is the most frequent malignant tumor
of the endocrine system and accounts for nearly 1% of
total human cancers [1]. Medullary thyroid carcinoma
(MTC) is a malignancy of the parafollicular C cells derived
from neural crest. MTC represents 5–10% of all types of
thyroid cancers [2–4] and occurs in both sporadic (75%)
and hereditary (25%) forms. The latter has an autosomal
dominantmode of inheritance with variable expressivity and
anage-relatedpenetrance[5,6].ThisformofMTCisdivided
into3subtypes:isolatedFamilial MTC(FMTC)andmultiple
endocrine neoplasia type 2A and 2B (MEN2A, 2B). Aﬀected
individualsinFMTCdevelopMTCwithoutany otherabnor-
malities. MEN2A is characterized by MTC, pheochromocy-
toma,and parathyroid hyperplasia (75% ofhereditary MTC)
and MEN2B is characterized by MTC, pheochromocytoma,
mucosal neuromas, ganglioneuromatosis of the gut, and a
Marfanoid habitus (MEN2B) [5–8]. The gene(s) responsible
for FMTC, MEN2A, and MEN2B were mapped on chro-
mosome 10q11.2 by genetic linkage analysis [9]. Rearranged
during transfection (RET) proto-oncogene is located on
10q11.21 chromosome [10] within the candidate region and
has 21 exons and its point mutations have been identiﬁed in
FMTC, MEN2A, and MEN2B. This proto-oncogene encodes
a single-pass transmembrane receptor with a tyrosine kinase
activity that is crucial in signal transduction during cell
growth and diﬀerentiation [11]. The RET receptor in cell
membrane is composed of one cystein rich residue, four
cadherin-like repeats, and one calcium binding site in ex-
tracellular portion and contains tyrosine kinase domain in
intracellular portion [12–14]. Upon ligand binding, RET
dimerization is induced and mutual transphosphorylation
of tyrosine residues occurs [15].2 Journal of Thyroid Research
RET proto-oncogene loss of function results in Hirch-
s p r u n gd i s e a s ea n di t sg a i no ff u n c t i o ni si m p l i c a t e di na
number of cancer syndromes such as MTC [13, 15]. As
RET is a proto-oncogene, a single activating mutation in its
one allele is suﬃcient to cause neoplastic changes [16].
Hereditary MTC is caused by germline mutations in the RET
proto-oncogene and its somatic mutations is implicated in
the sporadic MTC [2, 17] .T h em o s tf r e q u e n tm u t a t i o n si n
the RET proto-oncogene have been found in ﬁve cysteine
codons 609, 611, 618, and 620 of exon 10 and codon 634 of
exon 11. In addition, some other mutations have also been
identiﬁed in noncystein codons such as 804 in exon 14,
883 in exon 15, and 918 in exon 16 [18, 19]. A germline
mutation in this proto-oncogene has been observed in more
than 95% of MEN2 patients [3] and several studies have
found that point mutations are the extracellular domain
in more than 96% MEN2A and 86% FMTC patients [13,
20]. These mutations induce RET proto-oncogene catalytic
activity through disulﬁde homodimerization even in ligand
absence [21–24]. Germline mutations also occur in the RET
intracellular domain in codons 768, 790, and 791 (exon 13),
codons 804, 844 (exon 14), and codon 891 (exon 15) in the
FMTC [25] and codon 918 (exon 16) in MEN2B patients
[16].
The early diagnosis of carrier RET mutation individuals,
which are susceptibletodevelopMTC laterinlife,is possible.
Genetic screening especially is useful for ﬁrst-degree kindred
of MTC patients. The aim of this study was to determine the
allele frequency of predominant RET germline mutations in
exons10,11,and16amongIranianhereditaryMTCpatients.
2.Materialsand Methods
2.1. Patients. The study populationconsisted of 217 individ-
uals, including 151 patients and 66 their ﬁrst-degree relatives
diagnosed for MTC between 2002 and 2010. They were
referred to Research Institute for Endocrine Sciences, Shahid
Beheshti University of Medical Science and the volunteer
individuals were included in the survey after obtaining an
informed consent. The diagnosis of MTC was conﬁrmed by
histopathologic documents. After germline RET mutation
analysis, the ﬁrst-degree relatives of MTC patients with
positive mutations were also examined for RET mutations.
This study has been approved by the Institutional Review
Board and Ethics Committee of Obesity Research Center,
Research Institute for Endocrine Sciences, Shahid Beheshti
University of Medical Sciences.
2.2. RET Genetic Analysis. Blood samples were collected in
EDTA from all 217 subjects. Genomic DNA was extracted
from peripheral leucocytes samples according to a Standard
Salting-out/Proteinase K method. An aliquot of DNA for
each individual was stored at −20◦C.
The RET gene exons 10, 11, and 16 were analyzed in
a l ls u b j e c t su s i n gP C R - R F L Pm e t h o d s[ 22, 23]. For positive
patients, sequencing was carried out in both sense and
antisense direction.
For ampliﬁcation of the DNA segment containing RET
exon 10, the following primers were used: (10F 5 GCG-
CCCCAGGAGGCTGATGC3 ) and (10R 5 CGTGGTGGT-
CCCGGCCGCC3 ). The RET exon 11 was ampliﬁed using
following primers: (11AF 5 CCTCTGCGGTGCCAAGCC-
TC3 )and(11AR5 CACCGGAAGAGGAGTAGCTG3 )[23,
24, 26]. Ampliﬁcation was carried out in a volume of
50μL containing 1.5μLo f1 0 ×buﬀer, 50ng DNA, 0.3μL
of each dNTPs (10mM) (Boehringer Mannheim Co.), 1μL
of each exons 10 and 11 primers (10μM) (TIB MOLBIOL
Synthesalabor Co.), 0.25μLM g C l 2 (50mM), and one U
Taq polymerase (Boehringer Mannheim Co.). PCR reaction
for both exons 10 and 11 was 30 cycles and performed
in an automatic thermocycler (Omnigene & Hybaid Co.)
under the following conditions: denaturation at 93◦Cf o r
45seconds, annealing at 67◦C for 30seconds and extension
at 72◦C for another 45seconds, and ﬁnal extension at 72◦C
for 10minutes [18, 27].
For ampliﬁcation of the DNA segment containing RET
exon 16, the following primers were used: (16F 5 GTGCCC-
AGGAGTGTCTACCA3 ) and (16R 5 CAGGACCACAGG-
AGGGTAAC3 ). A PCR reaction of exon 16 was performed
in a 15μL mixture containing 50ng DNA, 0.35μLo f
MgCl2 (50mM), 0.5μL ofeachdNTPs (10mM) (Boehringer
Mannheim Co.), 0.6μLo fe a c he x o n1 6p r i m e r s( 1 0 μM)
(TIB MOLBIOL Synthesalabor Co.), 1.5μLo f1 0× buﬀer,
and one U Taq polymerase (Boehringer Mannheim Co.).
PCR reaction for exon 16 was 30 cycles and performed
in an automatic thermocycler (Omnigene & Hybaid Co.)
under the following conditions: denaturation at 92◦Cf o r
10minutes and 93◦C for 45seconds, annealing at 59.5◦C
for 30seconds, extension at 72◦C for 55seconds, and ﬁnal
extension at 72◦Cf o r1 0m i n u t e s[ 27–29].
The ampliﬁed PCR products were digested by each of
Taq I, BstU I, Mbo II, Rsa I, Nla IV (England Biolabs), and
Cfo I (Roehe Molecular Biochemicals) restriction enzymes
for exon 10. The products were digested with the following
restriction enzymes Cfo I, Rsa I, Hae III, and Dde I for exon
11, and FokI for exon 16 (England Biolabs) in the restriction
buﬀer according to the manufacturer’s instructions [10,
27, 28]. The RFLP-produced patterns by these restriction
enzymes in the presence and absence of each RET exon
10, 11, and 16 mutations have been shown in Table 1.T h e
digestedsampleswere separatedbyelectrophoresisthrougha
10% nondenaturing polyacrylamide gel electrophoresis and
thendetectedbysilver staining method.The positivesamples
for RET mutation then were sequences.
3.Results
Altogether, 217 individuals, including 126 females and 91
males, participated in this study and the overall female-to-
male ratio was 1.4:1. Among these, 151 individuals were
diagnosed with MTC (88 females and 63 males) and 66
individuals were their ﬁrst-degree relatives. The mean age of
individuals was 33.4±15.8 years. Genetic analyses revealed a
germline RET missense mutation in 43 out of 217 (19.8%)
individuals that 24 mutations occurred in female and 19
mutations were in male. From RET positive individuals, 36
mutations were in patients and sevenmutations were in theirJournal of Thyroid Research 3
Table 1: Characterization and distribution of RET proto-oncogene germ-line mutations in exons 10, 11, 16, and intron 16 among patients
with MTC and their families.
RET
mutation
Exon Changed bp
Normal (Mutant) Frequency Families
C611W 10 TGC (TGG) 0 0
C618Y 10 TGC (TAC) 5 2
C618R 10 TGC (CGC) 1 1
C618F 10 TGC (TTC) 4 4
C618S 10 TGC (AGC) 1 1
C620R 10 TGC (CGC) 1 1
C620F 10 TGC (TTC) 1 1
C634R 11 TGC (CGC) 1 1
C634Y 11 TGC (TAC) 5 3
C634G 11 TGC (GGC) 11 9
C634W 11 TGC (TGG) 1 1
C634S 11 TGC (AGC) 9 2
S686N 11 AGC>AAC 1 1
M918T 16 ATG (ACG) 2 2
Intron 16 A>T (rs3026772) 2 2
45044G>A1 1
45095C>A4 1
45190C>A1 1
ﬁrst-degree relatives. Moreover, the mutations found in this
study are belonging to the independent families.
In this study the majority of RET mutations (28 of 43,
65.1%) were located in exon 11 (11 C634G, nine C634S, ﬁve
C634Y, one C634R, one C634W, and one S686N) (Figure 1).
Interestingly, one of the positive RET patients had a new
restriction site in exon 11 for CfoI restriction enzyme, but
its cut fragments on a poly acryl amid gel were diﬀered
from another positive patients who had this restriction site
(C634R). With direct DNA sequencing of exon 11 of this
patient, a new missense mutation was detected at codon
686 (Ser686Asn, AGC>AAC) that has been not reported yet.
This patient was an 18-year-old girl who had underwent
thyroidectomyforthyroidnodulesabout2yearsago,andher
father suﬀered from very aggressive MTC.
Theother15mutationswerefoundinexons10and16.In
particular, 13 of 43 mutations (30.2%) were in exon 10 (ﬁve
C618Y, four C618F, one C618S, one C618R, one C620F, and
one C620R). In addition, two of 43 mutations (4.6%) were
identiﬁed at codon 918 of exon 16 (M918T). One of these
patients was a 14-year-old girl with early-diagnosed MTC.
This mutation was found only in this patient although her
p a r e n t sw e r en o r m a ls u g g e s t i n gt h a ti tm a yb ead en o v o
mutation. The other patient with M918T mutation was a
boy that had been thyroidectomized when he was 10-year-
old and he was diagnosed for early MTC. Unfortunately, he
died when he was 19-year-old, because of distant metastasis
to lung and brain.
Additionally, in the present study four sequence varia-
tions were detected in intron 16 of the RET proto-oncogene
in seven patients and one their relatives, which three of those
were new variations. These polymorphisms include A>T
(rs3026772), 45044G>A, 45095C>A, and 45190C>A. A ﬁrst
variant, A>T (rs3026772), was identiﬁed in intron 16 in
2p a t i e n t sa ﬀected to MTC. A second variant, 45044G>A,
was detected in a patient that had a mutation in codon
634 (C634S). A third variant, 45095C>A, was identiﬁed in
a family (4 individuals) with MEN2B where all of them
carried a mutation in codon 611 (C611Y). The last variant,
45190C>A, was in a patient diagnosed for MTC with
additional mutation in codon 620 (C620R).
4.Discussion
In present study, by mutational screening of the RET
proto-oncogene we found 43 germline mutations in the
predominant codons of exons 10, 11, and 16 among 217
individuals with MTCs. All of these encode cysteine codon
618 or 620 in exon 10 (30.2%) and cysteine codon 634
in exon 11 (65.1%), except of two (4.6%) mutations that
occurred in codon 918 in exon 16 (M918T) and one new
mutation that found in codon 686 in exon 11 (S686N). In
this investigation, overall frequency proﬁle of RET proto-
oncogene germline mutation in Iranian MTC patients was
estimated 19.8%.
Mutations of the extracellular RET cysteine-rich domain
at codons 634, 609, 611, 618, and 620 resulted in ligand-
independent dimerization of receptor molecules, enhanced
phosphorylation ofintracellularsubstrates, and celltransfor-
mation. Germline mutations in codons 609, 611, 618, 620,
634, and 768 have been discovered predominantly in MEN4 Journal of Thyroid Research
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Figure 1: The allele frequency of the RET proto-oncogene muta-
tions in Iranian patients with MTC.
2AandFMTC[27–29].Mutationoftheintracellulartyrosine
kinase (codon 918) has no eﬀect on receptor dimerization
but causes constitutive activation of intracellular signaling
pathways and also results in cellular transformation. It is
demonstrated that patients with codon 918 mutations and
MEN2B have a high risk of aggressive MTC occurring at a
young age [29].
The mutations at codon 634, known as a common
mutation in Caucasians [26], accounted for 65.1% of all
mutations found in Iranian patients with MTC, in our study.
Among ﬁve diﬀerent types of nucleotide substitution found
in this codon, changes from Cys to Gly (11 of 43) were the
most common, followed by CystoSer(9 of43),Cysto Tyr (5
of 43), Cys to Arg (one of 43), and Cys to Trp (one of 43). A
comparison of our data with those available in the literature
on other Caucasians indicates that the common alteration
from Cys634Gly in this study may represent a founder
eﬀect.Indeed it has beenreported that Cys634Arg mutation-
that is the most common mutation in MTC patients in
many population—is related to parathyroid diseases [30].
However, this mutation is rare in our population (identiﬁed
i no n ep a t i e n t ,o n l y ) .H o w e v e r ,i nt h ev e r yr e c e n ts t u d y
that carried out by Alvandi et al. in Iran, the most frequent
mutation was Cys634Arg (ﬁve mutations in 55 patients).
This diﬀerent result in comparison with our study may
be related to diﬀerent genetic background of those studied
population [31].
Fern´ andez et al. in a study showed that the most
frequent RET mutation in MEN 2A Spanish families is
C634Y [32]. The RET proto-oncogene mutation analyses in
French hereditary MEN2A and their ﬁrst-degree relatives
revealed that the most frequent mutation in this popula-
tion was C634R and C634Y [29, 33]. In contrast, more
prevalent mutation in FMTC in Sardinia was observed in
codon 804 (V804M) and the less frequent mutant allele
was present in codon 634 [34]. Also, high prevalence of
RET mutations in the hereditary type of MTC has been
found in codons 634 (C634R), 918 (M918T), 768, and
804 in American population [19]. Another study in China
showed that the highest frequency of the RET mutation in
patients with hereditary MTC was in codon 634 (C634Y)
and 918 (M918T) in MEN2A and MEN2B, respectively.
H o w e v e r ,t h em o s tf r e q u e n tR E Tproto-oncogene mutations
in Saudi’s families with MEN2A and FMTC [35]a n di n
the Netherlands population with FMTC were at codon 618
[19]. A mutation rate in codon 918 (M918T) was high in
sporadic type of MTC in Portugal, Czech Republic, and Italy
population [2–4, 33, 36]. However, we identiﬁed only two
M918T germline mutations in studied population, which in
comparison with other population is low.
In general, it is apparent that the prevalence of RET
proto-oncogene mutations in most Caucasian population
may be related to codon 634 and codon 918. The present
study also is in agreement with these reports, except for
codon 918.
We showed the frequency proﬁle of RET proto-oncogene
mutations in a sample of 151 Iranian MTCs and 66 their
relatives. These results underline the importance of the
geneticbackgroundinthedistributionofRETmutationsand
should be taken into account in genetic evaluation of MTC
patients.
Finally, it is suggested that other RET exons especially
those with high frequency of mutations such as exons
13, 14, and 15 should be examined. Direct sequencing
analysis is also an accurate method to detect unknown
RET mutations. Furthermore, a transforming activity and
functional eﬀect(s)ofa newRETmutantssuch asS686Nand
intronic polymorphisms remain to be elucidated.
Acknowledgments
This study was supported by a research grant from the
Endocrine Research Center, Shahid Beheshti University of
Medical Sciences. The authors are indebted to kind collab-
oration of several endocrinology specialists. They express
their gratitude to the staﬀ of molecular genetic laboratory
at the Endocrine Research Center, for their skillful technical
assistance.
References
[1] M. N. Nikiforova and Y. E. Nikiforov, “Molecular genetics
of thyroid cancer: implications for diagnosis, treatment and
prognosis,” Expert Review of Molecular Diagnostics,v o l .8 ,n o .
1, pp. 83–95, 2008.
[2] S. Dvor´ ak´ a, E. V´ aclav´ ıkov´ a, V. S´ ykorov´ ae ta l . ,“ N e wm u l t i p l e
somaticmutationsintheRETproto-oncogeneassociatedwith
a sporadic medullary thyroid carcinoma,”Thyroid, vol.16,no.
3, pp. 311–316, 2006.Journal of Thyroid Research 5
[ 3 ]M .M .M o u r a ,B .M .C a v a c o ,A .E .P i n t oe ta l . ,“ C o r r e l a t i o n
of RET somatic mutations with clinicopathological features
in sporadic medullary thyroid carcinomas,” British Journal of
Cancer, vol. 100, no. 11, pp. 1777–1783, 2009.
[ 4 ]D .J .M a r s h ,D .L .L e a r o y d ,a n dB .G .R o b i n s o n ,“ M e d u l l a r y
thyroid carcinoma:recent advances andmanagementupdate,”
Thyroid, vol. 5, no. 5, pp. 407–424, 1995.
[5] R. Elisei, B. Cosci, C. Romei et al., “Prognostic signiﬁcance
of somatic RET oncogene mutations in sporadic medullary
thyroid cancer: a 10-year follow-up study,” Journal of Clinical
Endocrinology &Metabolism,vol.93,no.3,pp. 682–687,2008.
[6] R. S. Sippel, M. Kunnimalaiyaan, and H. Chen, “Current
managementof medullary thyroid cancer,” Oncologist, vol. 13,
no. 5, pp. 539–547, 2008.
[7] R. V. Thakker, “Multiple endocrine neoplasia—syndromes of
the twentieth century,” Journal of Clinical Endocrinology &
Metabolism, vol. 83, no. 8, pp. 2617–2620, 1998.
[8] H. Donis-Keller, S. Dou, D. Chi et al., “Mutations in the RET
proto-oncogene are associated with MEN 2A and FMTC,”
Human Molecular Genetics,vol. 2, no. 7, pp. 851–856, 1993.
[ 9 ]C .G .P .M a t h e w ,K .S .C h i n ,D .F .E a s t o ne ta l . ,“ Al i n k e d
genetic marker for multiple endocrine neoplasia type 2A on
chromosome 10,” Nature, vol. 328, no. 6130, pp. 527–528,
1987.
[10] S.Shirahama,K.Ogura,H. Takamiet al.,“Mutationalanalysis
of the RET proto-oncogene in 71 Japanese patients with
medullarythyroidcarcinoma,”JournalofHumanGenetics,vol.
43, no. 2, pp. 101–106, 1998.
[11] S. Mani´ e, M. Santoro, A. Fusco, and M. Billaud, “The
RET receptor: function in development and dysfunction in
congenital malformation,” Trends in Genetics, vol. 17, no. 10,
pp. 580–589, 2001.
[12] M. P. Cosma,M. Cardone, F. Carlomagno,and V. Colantuoni,
“Mutations in the extracellular domain cause RET loss of
function by a dominant negative mechanism,” Molecular and
Cellular Biology, vol. 18, no. 6, pp. 3321–3329, 1998.
[13] S. Bethanis, G. Koutsodontis, T. Palouka et al., “A newly
detected mutation of the RET protooncogene in exon 8 as a
cause of multiple endocrine neoplasia type 2A,” Hormones,
vol. 6, no. 2, pp. 152–156, 2007.
[14] J. Grimm, M. Sachs, S. Britsch et al., “Novel p62dok family
members, dok-4 and dok-5, are substrates of the c-Ret recep-
tor tyrosine kinase and mediate neuronal diﬀerentiation,”
J o u r n a lo fC e l lB i o l o g y , vol. 154, no. 2, pp. 345–354, 2001.
[ 1 5 ]C .J .M .L i p s ,J .W .M .H ¨ oppener, and J. H. H. Thijssen,
“Medullary thyroid carcinoma: role of genetic testing and
calcitonin measurement,” Annals of Clinical Biochemistry,v o l .
38, part 3, no. 3, pp. 168–179, 2001.
[16] R.Elisei,C.Romei,B.Cosci,L.Agate,V .Bottici,E.Molinaroet
al., “RET genetic screening in patients with medullary thyroid
cancer and their relatives: experience with 807 individuals at
one center,” Journal of Clinical Endocrinology & Metabolism,
vol. 92, no. 12, pp. 4725–4729, 2007.
[17] N. Wohllk, G. J. Cote, M. M. J. Bugalho et al., “Relevance of
RETproto-oncogenemutationsinsporadicmedullarythyroid
carcinoma,” Journal of Clinical Endocrinology & Metabolism,
vol. 81, no. 10, pp. 3740–3745, 1996.
[18] M. Lallier, D. St-Vil, M. Giroux et al., “Prophylactic thyroidec-
tomy for medullary thyroid carcinoma in gene carriers of
MEN2 syndrome,” Journal of Pediatric Surgery, vol. 33, no. 6,
pp. 846–848, 1998.
[19] C. Eng, D. Clayton, I. Schuﬀenecker, G. Lenoir, G. Cote,
R. F. Gagel et al., “The relationship between speciﬁc RET
proto-oncogene mutations and disease phenotype in multiple
endocrine neoplasia type 2. International RET mutation con-
sortium analysis,”Journal of the American Medical Association,
vol. 276, no. 19, pp. 1575–1579, 1996.
[20] S. Chappuis-Flament, A. Pasini, G. de Vita et al., “Dual eﬀect
on the RET receptor of MEN 2 mutations aﬀecting speciﬁc
extracytoplasmic cysteines,” Oncogene, vol. 17, no. 22, pp.
2851–2861, 1998, Laboratoire de G´ en´ etique, CNRS UMR
5641, Domaine Rockefeller, Lyon, France.
[21] M. Santoro, F. Carlomagno, A. Romano et al., “Activation of
RET as a dominant transforming gene by germline mutations
of MEN2A and MEN2B,” Science, vol. 267, no. 5196, pp. 381–
383, 1995.
[22] C. Eng, P. A. Crossey, L. M. Mulligan et al., “Mutations
in the RET proto-oncogene and the von Hippel-Lindau
disease tumour suppressor gene in sporadic and syndromic
phaeochromocytomas,” Journal of Medical Genetics,v o l .3 2 ,
no. 12, pp. 934–937, 1995.
[23] M. Hedayati, I. Nabipour, N. Rezaei-Ghaleh, and F. Azizi,
“Germline RET mutations in exons 10 and 11: an Iranian
survey of 57 medullary thyroid carcinoma cases,” Medical
Journal of Malaysia, vol. 61, no. 5, pp. 564–569, 2006.
[24] M. Hedayati, M. Zarif Yeganeh, M. Daneshpour, M. Ahmadi,
and F. Azizi, “Frequent germline mutation in RET proto-
oncogene exons 10 and 11 in hereditary MTC of Iranian
patients,” Kowsar Medical Journal, vol. 15, no. 1, pp. 17–21,
2010.
[ 2 5 ]Y .Z h o u ,Y .Z h a o ,B .C u ie ta l . ,“ R E Tp r o t o - o n c o g e n em u t a -
tionsare restricted to codons634 and918in mainlandchinese
families with MEN2A and MEN2B,” Clinical Endocrinology,
vol. 67, no. 4, pp. 570–576, 2007.
[26] L. M. Mulligan, C. Eng, C. S. Healey et al., “Speciﬁc mutations
oftheRET proto-oncogeneare related to diseasephenotypein
MEN 2Aand FMTC,” Nature Genetics,vol.6,no.1, pp. 70–74,
1994.
[27] A. Machens, P. Niccoli-Sire, J. Hoegel et al., “Early malignant
progression of hereditary medullary thyroid cancer,” The New
England Journal of Medicine, vol. 349, no. 16, pp. 1517–1525,
2003.
[28] K. Frank-Raue, A. Machens, C. Scheuba, B. Niederle, H.
D r a l l e ,a n dF .R a u e ,“ D i ﬀerence in development of medullary
thyroid carcinoma among carriers of RET mutations in
codons 790 and 791,”Clinical Endocrinology,v o l .6 9 ,n o .2 ,p p .
259–263, 2008.
[29] I. Schuﬀenecker, M. Virally-Monod, R. Brohet et al., “Risk
and penetrance of primary hyperparathyroidism in multiple
endocrine neoplasiatype 2A families with mutationsat codon
634 of the RET proto-oncogene. Groupe d’etude des tumeurs
` a calcitonine,”Journal of Clinical Endocrinology & Metabolism,
vol. 83, no. 2, pp. 487–491, 1998.
[30] E. Saggiorato, I. Rapa, F. Garino et al., “Absence of RET
gene point mutations in sporadic thyroid C-cell hyperplasia,”
Journal of Molecular Diagnostics, vol. 9, no. 2, pp. 214–219,
2007.
[31] E. Alvandi, S. M. Akrami, M. Chiani et al., “Molecular
analysisofthe RET proto-oncogene key exons in patients with
medullary thyroid carcinoma: a comprehensive study of the
Iranian population,” Thyroid, vol. 2, no. 4, pp. 373–382, 2011.
[32] R. M. Fern´ andez, E. Navarro, G. Anti˜ nolo, M. Ruiz-Ferrer,
and S. Borrego, “Evaluation of the role of RET polymor-
phisms/haplotypes as modiﬁer loci for MEN 2, and analysis
of the correlation with the type of RET mutation in a series of
Spanish patients,” International Journal of Molecular Medicine,
vol. 17, no. 4, pp. 575–581, 2006.6 Journal of Thyroid Research
[ 3 3 ]I .B e r a r d ,J .L .K r a i m p s ,F .S a v a g n e re ta l . ,“ G e r m l i n e -
sequence variants S836Sand L769L in the RE arranged during
transfection (RET) proto-oncogene are not associated with
predisposition to sporadic medullary carcinoma in the french
population,” Clinical Genetics, vol. 65, no. 2, pp. 150–152,
2004.
[34] G. Pinna, G. Orgiana, A. Riola et al., “RET proto-oncogene in
Sardinia: V804M is the most frequent mutation and may be
associated with FMTC/MEN-2A phenotype,” Thyroid, vol. 17,
no. 2, pp. 101–104, 2007.
[35] TNasser,F.Qari,AKarawgh,andJ.AlAama,“RET codon618
mutations is the most frequent phenotype in Saudi families
with multiple endocrine neoplasia type 2A,” in Proceedings
of the European Congress of Endocrinology, vol. 22, p. 380,
European Society of Endocrinology, Prague, Czech Republic,
April 2010.
[36] M. Robledo, L. Gil, M. Poll´ an et al., “Polymorphisms
G691S/S904SofRET asgenetic modiﬁers ofMEN 2A,”Cancer
Research, vol. 63, no. 8, pp. 1814–1817, 2003.